INOZYME PHARMA INC's ticker is INZY and the CUSIP is 45790W108. A total of 38 filers reported holding INOZYME PHARMA INC in Q4 2022. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $385,069 | -40.7% | 91,683 | -21.4% | 0.01% | -43.8% |
| Q2 2023 | $649,462 | -3.5% | 116,600 | -0.7% | 0.02% | -11.1% |
| Q1 2023 | $672,702 | +380.3% | 117,400 | -12.0% | 0.02% | +350.0% |
| Q4 2022 | $140,070 | -60.9% | 133,400 | 0.0% | 0.00% | -60.0% |
| Q3 2022 | $358,000 | -14.1% | 133,400 | +52.6% | 0.01% | 0.0% |
| Q2 2022 | $417,000 | +77.4% | 87,400 | +52.3% | 0.01% | +100.0% |
| Q1 2022 | $235,000 | -55.5% | 57,400 | -25.8% | 0.01% | -50.0% |
| Q4 2021 | $528,000 | – | 77,400 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Pivotal bioVenture Partners Investment Advisor LLC | 1,591,154 | $18,441,000 | 6.52% |
| CHI Advisors LLC | 920,264 | $10,666,000 | 3.11% |
| Sofinnova Investments, Inc. | 2,028,308 | $23,508,000 | 1.39% |
| MPM BioImpact LLC | 320,724 | $3,717,000 | 0.58% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,344,786 | $27,176,000 | 0.53% |
| NEA Management Company, LLC | 2,444,379 | $28,330,000 | 0.34% |
| Rock Springs Capital Management LP | 850,015 | $9,852,000 | 0.21% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 986,400 | $11,432,000 | 0.19% |
| Overbrook Management Corp | 16,726 | $194,000 | 0.04% |
| Orbimed Advisors | 294,000 | $3,407,000 | 0.04% |